Portal de Periódicos da CAPES

Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19

2022; American College of Physicians; Volume: 175; Issue: 8 Linguagem: Inglês

10.7326/m22-0729

1539-3704

Matthew G. Johnson, Amy Puenpatom, Pablo Andrés Moncada, Lesley Burgess, Elizabeth R. Duke, Norio Ohmagari, Timo Wolf, Matteo Bassetti, Sanjay Bhagani, Jade Ghosn, Ying Zhang, Hong Wan, Angela Williams‐Diaz, Michelle Brown, Amanda Paschke, Carisa De Anda,

Respiratory viral infections research

In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progression to severe disease.